Baker Brothers Advisors - CYMABAY THERAPEUTICS INC ownership

CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 113 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of CYMABAY THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$13,608,809
+79.1%
2,170,4640.0%0.08%
+64.0%
Q3 2022$7,597,000
+18.6%
2,170,4640.0%0.05%
+38.9%
Q2 2022$6,403,000
-5.1%
2,170,4640.0%0.04%
-7.7%
Q1 2022$6,750,000
-8.0%
2,170,4640.0%0.04%
+8.3%
Q4 2021$7,336,000
-7.4%
2,170,4640.0%0.04%
+2.9%
Q3 2021$7,922,000
-16.3%
2,170,4640.0%0.04%
-16.7%
Q2 2021$9,463,000
-4.0%
2,170,4640.0%0.04%
-2.3%
Q1 2021$9,854,000
-40.7%
2,170,464
-25.0%
0.04%
-31.7%
Q4 2020$16,607,000
-29.5%
2,893,276
-11.0%
0.06%
-33.0%
Q3 2020$23,548,000
+343.0%
3,252,542
+113.6%
0.09%
+308.7%
Q2 2020$5,315,000
-81.8%
1,522,792
-73.3%
0.02%
-88.4%
Q3 2019$29,222,000
-28.5%
5,707,4110.0%0.20%
-28.4%
Q2 2019$40,865,000
-46.1%
5,707,4110.0%0.28%
-42.7%
Q1 2019$75,794,000
+95.8%
5,707,411
+16.1%
0.48%
+53.0%
Q4 2018$38,702,000
-29.0%
4,917,7000.0%0.32%
-11.7%
Q3 2018$54,488,000
-17.4%
4,917,7000.0%0.36%
-27.6%
Q2 2018$65,996,000
+29.7%
4,917,700
+25.5%
0.50%
+15.1%
Q1 2018$50,891,000
+84.9%
3,917,700
+30.9%
0.43%
+80.3%
Q4 2017$27,524,000
+14.1%
2,991,7750.0%0.24%
+21.9%
Q3 2017$24,114,000
+224.1%
2,991,775
+131.6%
0.20%
+201.5%
Q2 2017$7,441,000
+22.4%
1,291,775
-8.6%
0.06%
+30.0%
Q1 2017$6,078,000
+1036.1%
1,413,499
+357.0%
0.05%
+900.0%
Q4 2016$535,000309,2680.01%
Other shareholders
CYMABAY THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 1,787,094$26,645,57214.80%
Lynx1 Capital Management LP 994,161$14,822,9419.80%
Octagon Capital Advisors LP 3,073,750$45,829,6137.04%
Saturn V Capital Management LP 1,124,459$16,765,6847.02%
Altium Capital Management LP 800,000$11,928,0006.22%
Affinity Asset Advisors, LLC 1,129,376$16,838,9964.74%
ACUTA CAPITAL PARTNERS, LLC 418,000$6,232,3804.18%
Cormorant Asset Management, LP 3,850,000$57,403,5003.35%
SILVERARC CAPITAL MANAGEMENT, LLC 590,000$8,796,9002.67%
MPM BioImpact LLC 610,770$9,106,5812.43%
View complete list of CYMABAY THERAPEUTICS INC shareholders